FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC
A drug targeting FGFR mutations shows early promise for treating lung cancers with this genetic change.
This PubMed-indexed observational/cohort study examined FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC. The abstract reports that according to the first stage of the two-stage Simon's design, erdafitinib showed preliminary efficacy in NSCLC with FGFR fusions.
What the study was
- Study design
- Observational/cohort study
- Population
- FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC.
- Sample size
- 22
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Clinical cancer research : an official journal of the American Association for Cancer Research
Why it surfaced
Observational/cohort study with an abstract-supported finding relevant to Precision oncology and genomic medicine; scored conservatively because only the PubMed abstract was reviewed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.